# Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

> **NCT06809140** · PHASE2 · RECRUITING · sponsor: **Matthew Galsky** · enrollment: 47 (estimated)

## Conditions studied

- Muscle Invasive Bladder Urothelial Carcinoma

## Interventions

- **DRUG:** Enfortumab vedotin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06809140
- **Lead sponsor:** Matthew Galsky
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2027-11
- **Final completion:** 2029-11
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06809140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06809140, "Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06809140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*